Appl. No. 10/525,986
Response to Office Action mailed April 18, 2008

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (original) A therapeutic agent for glaucoma comprising a combination of a Rho kinase inhibitor and a prostaglandin.

Claim 2. (currently amended) A therapeutic agent for glaucoma characterized in that it which comprises a combination of a Rho kinase inhibitor and a prostaglandin, and they complement wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or enhance their actions enhanced by each other.

Claim 3. (previously presented) The therapeutic agent for glaucoma as claimed in claim 1, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-

-2-

Appl. No. 10/525,986 Response to Office Action mailed April 18, 2008

isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 4. (previously presented) The therapeutic agent for glaucoma as claimed in claim 1, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 5. (original) A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a prostaglandin to a patient.

Claim 6. (currently amended) A method of treating glaucoma characterized by comprising administering effective amounts of a Rho kinase inhibitor in combination with a prostaglandin to a patient, thereby they complementing wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or enhancing their actions enhanced by each other.

Claim 7. (previously presented) The method of treating glaucoma as claimed in claim 5, wherein the Rho kinase

inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 8. (previously presented) The method of treating glaucoma as claimed in claim 5, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 9. (cancelled)

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 12. (cancelled)

Claim 13. (previously presented) The therapeutic agent for glaucoma as claimed in claim 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)

cyclohexanecarboxamide, (R) - (+) - N - (1H-pyrrolo[2,3-b]pyridin-4-yl) - 4 - (1-aminoethyl) benzamide, <math>1 - (5-isoquinolinesulfonyl) - homopiperazine or <math>1 - (5-isoquinolinesulfonyl) - 2 - methylpiperazine.

Claim 14. (previously presented) The therapeutic agent for glaucoma as claimed in claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 15. (previously presented) The therapeutic agent for glaucoma as claimed in claim 3, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 16. (previously presented) The therapeutic agent for glaucoma as claimed in claim 13, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 17. (previously presented) The method of treating glaucoma as claimed in claim 6, wherein the Rho kinase

inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 18. (previously presented) The method of treating glaucoma as claimed in claim 6, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 19. (previously presented) The method of treating glaucoma as claimed in claim 7, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

Claim 20. (previously presented) The method of treating glaucoma as claimed in claim 17, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.